Gallium-68/Fluorine-18 Prostate-Specific Membrane Antigen (Ga-68 PSMA/F-18 PSMA) has been shown to enable PET-guided treatment planning for prostate cancer metastases, including bone lesions, within RefleXion® 's BgRT workflow (43–45). This evidence concerns the gene FOLH1 and prostate carcinoma.